Could a simple supplement slow Parkinson's? new trial begins
NCT ID NCT07064005
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times
Summary
This early-stage study tests whether a supplement called gamma-glutamylcysteine (GGC) can increase levels of a key antioxidant, glutathione, in the brains of people with early Parkinson's disease. The goal is to see if this can help with movement problems, thinking skills, and gut health. The trial will involve 12 participants and uses brain scans and blood tests to measure changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSONS DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Presbyterian Hospital
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.